Details
Category: Volume 07 Issue 06 June 2019
Hits: 1435

Title: Association of Upper GI Bleed in Patients with Budesonide and SSRI Therapy in Chrons Disease: A Comparative Clinical Study

Authors: Rasmirekha Behera, Sushant Sethi

 DOI: https://dx.doi.org/10.18535/jmscr/v7i6.26

Abstract

Aim: To compare the association of Upper g.i bleed in patients with chron’s disease on Budesonide and SSRI therapy.

Methods: Total 30 patients of chrons disease were included for the study. Patients of both sexes with age group between 18-40 yrs were included. Patients were divided into two groups. Group I received Budesonide 9mg OD. Group II received SSRI in the dose of 40 mg/day. All patients were cases of chron’s disease. Budesonide 9mg OD were given to patients for remission of chron’s disease and SSRIs are given to patients of chron’s disease associated with depression. Both the drugs were given on daily basis for 6 months.

Result: All 30 patients included in the study were assessed for the presence of upper g.i bleed by G.I endoscopic and non-endoscopic parameters. The no of patients showing presence of upper g.i bleed is more in Group A in comparision to Group B.

Conclusion: Acute upper gastrointenstinal haemorrhage is a common medical emergency and mortality rate remains high as 6-8%.From this study it is concluded that patients of chron’s disease taking budesonide have high incidence of upper g.i bleed in comparision to patients with SSRIs.

Keyword: Upper G.I bleed, Chrons disease, SSRIs, Budesonide,

References

  1. Barkun A, Bardou M, Marshall JK. Consensus recommendations for managing patients with non variceal upper gastrointenstinal bleeding. Ann Intern Med 2003;139:843-57.
  2. Rockall TA, Logan RFA, Devlin HB, Northfield TC. Incidence of and mortality from acute upper gastrointenstinal hemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointenstinal Haemorrhage. BMJ. 1995;311:222-6.
  3. Hernandez-Diaz S, Rodriguez LA. Incidence of serious upper gastrointenstinal bleeding /perforation in the general population: review of epidemic studies. J Clin Epidemiol.2002;55:157-63.
  4. Lassen A,Hallas J, Schaffalitzky de Muckadell OB. Complicated and uncomplicated peptic ulcers in a Danish country 1993-2002:a population- based cohort study. Am J Gastroenterol 2006;101:945-53.
  5. Targownik LE, Nabalamba A. Trends in management and outcomes of acute nonvariceal upper gastrointenstinal bleeding: 1993-2003.Clin Gastroenterol Hepatol 2006;4:1459-66.
  6. Quan S,Frolkis A,Milne K, Molodecky N, Yang H, Dixon et al Upper-gastrointenstinal bleeding secondary to peptic ulcer disease: incidence and outcomes. World J Gastroenterol 2014;20:17568-77.
  7. Lu Y, Barkun AN, Martel M. Adherence to guidelines: a national audit of the management of acute upper gastrointenstinal bleeding. The REASON registry. Can J Gastroenterol Hepatol 2014;28:495-501.
  8. de Abajo FJ, Garcia-Rodrigez LA. Risk of upper gastrointenstinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: Interaction with nonsteroidal anti-inflammatory drugs and effect of acid suppressing agents. Arch Gen Psychiatry 2008;65:795-803.
  9. Targownik LE, Bolton JM, Metge CJ, Leung S, Sareen J. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointenstinal bleeding. Am J Gastroenterol 2009;104:1475-82.
  10. Tata LJ, Fortun PJ, Hubbard RB, Smeeth L, Hawkey CJ, Smith CJ, et al. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointenstinal bleeding. Ailment Pharmacol Ther 2005;22:175-81.
  11. Wessinger S, Kaplan M, Choi L, Williams M, Lau C, Sharp L,et al.Increase use of selective serotonin reuptake inhibitors in patients admitted with gastrointenstinal haemorrhage: a multicentre retrospective analysis. Aliment Pharmacol Ther 2006;23:937-44.
  12. Brenner B, Harney J T, Ahmed B A, Jeffus B C, Unal R, Mehta J L, and Kilic, F. Plasma serotonin levels and the platelet serotonin transporter. J Neurochem. 2007,206-215.
  13. Matondo R B, Punt C, Homberg J, Toussaint M J,Kisjes R et.al Deletion of the serotonin transporter in rats disturbs serotonin homeostasis without impairing liver regeneration. Am J Physiol. Gastrointest. Liver Physiol.296.
  14. Beikmann B S,Tomlison I D, Rosenthal S J and Andrews A M Serotonin uptake is largely mediated by platelets versus lymphocytes in peripheral blood cells.ACS Chem.Neurosci.4,161-170.
  15. Bismuth-Evenzal Y, Gonopolsky Y, Gurwitz D et al Decreased serotonin content and reduced agonist-induced aggregation in platelets of patients chronically medicated with SSRI drugs.J Affect Disord.2012;136,99-103.
  16. Carneiro A M, Cook E H, Murphy D L, and Blakely R D. Interactions between integrin αIIbβ3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans.J Clin Investig.2008;118:1544-1552.
  17. Abdelmalik N, Ruhe H G, Barwari K et al. Effect of the selective serotonin reuptake inhibitor paroxetine on platelet function is modified by a SLC6A4 serotonin transporter polymorphism. J Thromb Haemost.2008;6:2168-74.
  18. Namkung J, Kim H and Park S.Peripheral serotonin: a new player in systemic energy homeostasis. 2015;38:1023-1028.
  19. Hranilovic D, Blazevic S, Ivica N et al. The effects of the perinatal treatment with 5-hydroxytryptophan or tranylcypromine on the peripheral and central serotonin homeostasis in adult rats. Neurochem Int 2011;59,202-207.
  20. Gartside S E, Umbers V,Hajos M and Sharp T.(1995)Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: effects of 5-HT cell firing and extracellular 5-HT.Br J Pharmacol 115,1064-1070.
  21. Artigas F, Romero L, de Montigny C and Blier P (1996) Acceleration of the effect of selected antidepressant drugs in major depression by 5-HTIA antagonists. Trends Neurosci.19,378-383.
  22. Schmid C L, Raehal K M and Bohn L M (2008) Agonist-directed signaling of the serotonin 2A receptor depends on β-arrestin-2 interactions in vivo. Proc. Natl. Acad.Sci.USA.105,1079-1084.
  23. Bohn LM and Schmid C L.(2010) Serotonin receptor signaling and regulation via β-arrestins. Crit. Rev. Biochem. Mol.Biol.45,555-566.
  24. Cerrito F, Lazzaro M P, Gaudio E, Arminio P and Aloisi G,(1993) 5HT2-receptors and serotonin release:their role in human platelet aggregation. Life Sci.53,209-215.
  25. Thompson NT,Scrutton M C and Wallis R B (1986) synergistic responses in human platelets. Comparision between aggregation, secretion and cytosolic calcium concentration. Eur. J Biochem.161,399-408.
  26. Berger J S,Becker R C,Kuhn C et al(2013) Hyperreactive platelet phenotypes: relationship to altered serotonin transporter number,transport kinetics and intrinsic response to adrenergic co-stimulation.Thromb Haemost.109,85-92.
  27. Hirsh-Rokach,B Spectre,G Shai et al(2015) Differential impact of selective serotonin reuptake inhibitors on platelet response to clopidogrel: a randomized, double-blind, crossover trial. Pharmacotherapy 35,140-147.
  28. Halperin D,Reber G.Influence of antidepressants on hemostasis. Dialogues Clin Neurosci 2007:9(1)47-59.
  29. Ananthakrishnan AN. Environmental risk factors for inflammatory bowel diseases: a review.Dig Dis Sci.2015;60:290-298.
  30. Rietdijk ST, D’ Haens GR. Recent developments in the treatment of inflammatory bowel disease.J Dig Dis.2013;14:282-287.
  31. De Cassan C, Fiorino G, Danese S. Second-generation corticosteroids for the treatment of Chron’s disease and ulcerative colitis: more effective and less side effects.Dig Dis.2012;30:368-375.
  32. Khor B, Gardet A, Xavier RJ. Genetic and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307-317.
  33. Pappa HM, Langereis EJ, Grand RJ, Gordon CM. Prevalence and risk for hypovitaminosis D in young patients with Inflammatory bowel disease. J Pediatr Gastroenterol Nutr.2011;53:361-364.
  34. Loftus EV. Clinical epidemiology of inflammatory bowel disease: Incidence, Prevalence and environmental influences. Gastroenterology.2004;126:1504-1517.
  35. Hanauer SB, Sandborn W. Management of Chron’s disease in adults. Am J Gastroenterol 2001;96:635-43)]
  36. Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: a review of medical therapy.World J Gastroenterol. 2008;14:354-377.
  37. Ueno F, Matsui T,Matsumoto T, Matsuoka K, Watanabe M, Hibi T:Evidence-based clinical practice guidelines for Crohn’s disease integrated with formal consensus of experts in Japan. J Gastroenterol 2013;48:31-72.
  38. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG, Persson T: Oral budesonide for active Crohn’s disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994;331:836-841.
  39. Campieri M, Ferguson A, Doe W, Person T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Chron’s disease. The Global Budesonide Study Group. Gut 1997;41:209-14
  40. Rutgeerts P, Lofberg R, Malchow H, Lamers C ,Olaison G, Jewell D, et al. A comparision of budesonide with prednisolone for active Chron’s disease. N Eng J Med 1994;331:842-5.
  41. M. Clarke and K.C. Currie, Depression, anxiety and their relationship with chronic diseases: A review of epidemiology, risk and treatment evidence. Med J Aust vol 190,no.-7,pp.s54-s60,2009.
  42. B. Patten, Long-term medical conditions and major depression in a Canadian population study at waves 1&2,Journal of Affective Disorders,vol.63,no 1-3,35-41,2001.
  43. A .Graff, J.R. Walker and C.N. Bernstein, Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management, Inflammatory Bowel Diseases,vol 15,no 7,1105-1118,2009.
  44. K .Zhang, J Hewtt. Hemming et al.,The influence of depression on quality of life in patients with inflammatory bowel disease, Inflammatory Bowel Diseases,vol.19, no.8. 1732-1739,2013.
  45. Outpatient management of patients with low-risk upper-gastrointenstinal haemorrhage Multicentric validation and prospective evaluation. Stanley AJ, Ashley D, Dalton HR, Mowat C, et al; Lancet 2009;373:42-47.
  46. Rockall TA, Logan RF et al. Selection of patients for early discharge or outpatient care after acute upper gastrointenstinal haemorrhage. National Audit of Acute Upper Gastrointenstinal Haemorrhage. Lancet 1996;374:1138-1140.
  47. Rockall TA, Logan RFA, Devlin HB, Northfield TC.Incidence of and mortality from acute upper gastrointenstinal hemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointenstinal Haemorrhage. BMJ. 1995;311:222-6.
  48. Hernandez-Diaz S, Rodriguez LA. Incidence of serious upper gastrointenstinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol.2002;55:157-63.
  49. Adang RP, Vismans JF, Talmon JL etal. Appropriateness of indication for diagnostic upper gastrointenstinal endoscopy: association with relevant endoscopic disease. Gastrointest Endosc 1995;42:390-397.
  50. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial.Br Med J.1955;2:1041-1048.
  51. Ford AC, Bernsstein CN, Khan KJ et al Glucocorticosteroid therapy in inflammatory bowel disease: Systemic review and meta-analysis. Am J Gastroenterol.2011;106:590-599.
  52. Danese S, Hart A, Dignass A et al. Effectiveness of budesonide MMX (Cortiment) for the treatment of mild to moderate active ulcerative colitis: study protocol for a prospective multicentric observational cohort study.2016;3:000092.
  53. Sherlock ME, Mac Doland JK, Griffiths AM et al. Oral budesonide for induction of remission in Ulcerative colititis. Cochrane Database Syst Rev.2015;10: CD007698.

Corresponding Author

Rasmirekha Behera

Department of Pharmacology I.M.S & SUM Hospital Bhubaneswar